
LFWD Stock Forecast & Price Target
LFWD Analyst Ratings
Bulls say
Lifeward Ltd is projected to see its total revenues rise significantly, from $29.0 million in 2025 to $336.5 million by 2032, indicating a robust growth trajectory fueled by the increased placement of ReWalk and Alter-G systems along with improved reimbursement processes. The company demonstrated notable financial performance in the fourth quarter of 2024, achieving $7.5 million in revenue, marking a 23% quarter-over-quarter growth from the previous quarter and highlighting management's fiscal prudence. Additionally, the anticipated launch of the next-generation ReWalk 7.0 in 2025 and the expanded partnership with MYOLYN to enhance patient access to the MyoCycle FES Cycling Therapy System suggest promising avenues for sustainable revenue growth in the coming years.
Bears say
Lifeward Ltd is facing significant financial challenges, evidenced by recurring losses associated with the extinguishment of debt, which negatively impacts its cash flow and overall financial health. This situation suggests ongoing difficulties in managing debt obligations, raising concerns about the company's ability to sustain operations and pursue growth initiatives. Furthermore, the absence of clarity surrounding its financial recovery strategies may lead to heightened uncertainty among investors regarding the company’s long-term viability.
This aggregate rating is based on analysts' research of ReWalk Robotics Ltd and is not a guaranteed prediction by Public.com or investment advice.
LFWD Analyst Forecast & Price Prediction
Start investing in LFWD
Order type
Buy in
Order amount
Est. shares
0 shares